Literature DB >> 26921575

Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.

Jozef Visnovsky1, Erik Kudela1, Pavol Slavik2, Milan Krkoska1, Pavol Buocik1, Peter Szepe2, Jan Danko1.   

Abstract

OBJECTIVE: Uterine sarcomas are rare mesodermal malignant tumors with an incidence between 0.5 and 3.3 cases per 100,000 females per year. Most sarcomas are aggressive tumors leading to poor overall survival rates and only limited therapeutic options. The aim of this study was to evaluate the risk factors for uterine sarcomas and carcinosarcomas, and to identify the factors influencing the survival rate. SUBJECTS AND METHODS: We conducted a retrospective study with twenty-nine patients who were diagnosed with uterine sarcoma and thirty-four patients with carcinosarcoma between the years 1990 and 2006 at the Oncogynecologic center at the University Hospital in Martin, Slovakia. We focused on the analysis of the risk factors and survival rate of early stages I and II.
RESULTS: We confirmed highly statistically significant values for the inverse correlation between survival and tumor size, positive lymph nodes, high mitotic activity, vascular invasion, positive peritoneal cytology, elevated CA-125, smoking and BMI in sarcoma and carcinosarcoma group (p<0.001 for all factors). The use of lymphadenectomy had no effect on survival of all patients. DISCUSSION: Sarcomas and carcinosarcomas are aggressive tumors leading to poor overall survival rates and only limited therapeutic options. As there is no consensus on specific treatment, an individual approach based on evaluation of known risk factors is essential.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26921575

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  1 in total

1.  Significance of Malignant Peritoneal Cytology on Survival of Women with Uterine Sarcoma.

Authors:  Koji Matsuo; Shinya Matsuzaki; David J Nusbaum; Sohee Ki; Erica J Chang; Maximilian Klar; Lynda D Roman
Journal:  Ann Surg Oncol       Date:  2020-10-15       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.